7-OH Lawsuits Mount as DEA Classifies Certain Synthetic Kratom as Schedule I Controlled Substance

Federal regulators have moved to restrict synthetic kratom products by classifying three potent opioid compounds into Schedule I under the Controlled Substances Act. The U.S. Department of Justice announced on August 25, 2026, that the DEA was temporarily placing mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16 into the most restrictive federal drug category, which is reserved for substances with high abuse potential, no accepted medical use, and lack of accepted safety.

All three compounds are chemically related to 7-hydroxymitragynine (7-OH), a powerful opioid-like alkaloid that occurs naturally in kratom at trace levels but has become the focus of commercial laboratory processing and synthesis. Concentrated 7-OH products differ substantially from traditional botanical kratom and are being marketed and sold in increasingly potent forms.

Federal concerns center on addiction, respiratory depression, and other serious health risks associated with these synthetic derivatives. The Schedule I classification makes it illegal to manufacture, distribute, or possess these substances outside authorized research or limited circumstances. This regulatory action coincides with mounting litigation targeting kratom sellers and manufacturers of concentrated 7-OH products, particularly those making health or efficacy claims or failing to disclose addiction risks.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.